Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
Similar rates of percutaneous coronary intervention (PCI), coronary artery bypass grafting (CABG), and medical therapy for coronary artery disease (CAD) were found in patients with and without end-stage renal disease (ESRD).
ESRD alone does not influence the choice of therapy for CAD, researchers concluded in a presentation at the American College of Cardiology’s 68th Annual Scientific Session & Expo, held March 16-18 in New Orleans, Louisiana, and published in the Journal of the American College of Cardiology.1
Patients with ESRD, however, had significantly higher 30-day and 6-month readmission rates and longer hospital length of stay (LOS) than patients without ESRD.
In a retrospective study of 9027 patients who underwent cardiac catheterization from 2005 to 2015, 127 (1.4%) had ESRD and were on hemodialysis. Patients with and without ESRD showed no significant difference in the rates of PCI (33.3% vs 33.6%, respectively), CABG (35.9% and 30.2%, respectively), and medical therapy (30.8% and 36.2%, respectively) for CAD, Preetham Reddy Muskula, MBBS, and colleagues at Saint Louis University in Missouri, reported.
The 30-day and 6-month readmission rates were 17.3% and 35.4%, respectively, in the ESRD group compared with 9.6% and 16.9%, respectively, in the non-ESRD group. The average LOS was 4.5% in the ESRD group compared with 2.8 days in the non-ESRD group.
The ESRD and non-ESRD groups did not differ significantly with respect to age (59.7 vs 59.3, respectively), sex ratio (66.9% vs 63% men, respectively), and percentage of patients with obstructive CAD (61.4% vs 62.3%, respectively) and hypertension (35% vs 34%, respectively). The ESRD group had a significantly higher percentage of patients with diabetes vs the non-ESRD group (44.9% vs 18%, respectively).
Reference
Muskula PR, Alkhawam H, Ampadu J, Popp M, Helmy T. Analysis of treatment strategies and short-term outcomes for coronary artery disease in end-stage renal disease (ESRD) compared to non-ESRD patients following cardiac catheterization. Presented at: American College of Cardiology’s 68th Annual Scientific Session & Expo; March 16-18, 2019; New Orleans, LA. Abstract 1275-394.
